Advertisement

Topics

Pernix Therapeutics Holdings, Inc. Company Profile

08:56 EST 20th November 2017 | BioPortfolio

Pernix Therapeutics Holdings, Inc. is a specialty pharmaceutical company primarily focused on serving the needs of the pediatric marketplace. Commercially-proven branded product families include CEDAX®, BrovexTM, Aldex®, Pediatex®, ReZystTM, QuinZymeTM and Z-Cof®. The company was originally founded in 1999 and is based in the Houston, TX metropolitan area. Additional information is available on the Pernix website at www.pernixtx.com.


News Articles [852 Associated News Articles listed on BioPortfolio]

Pernix Therapeutics Holdings, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 12062017] Prices from USD $350

Pernix Therapeutics Holdings, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Pernix Therapeutics Holdings, Inc. Mergers Acquisitions MA, Partnerships...

Pernix Therapeutics Holdings, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment Report [Report Updated: 16102017] Prices from USD $350

Pernix Therapeutics Holdings, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's Pernix Therapeutics Holdings, Inc. Mergers Acquisitions MA, Partnerships...

Pernix sells SI Pharmaceuticals its Cedax for $2mm

SI Pharmaceuticals LLC acquired Pernix Therapeutics Holdings Inc.'s third-generation cephalosporin antibiotic Cedax (ceftibuten) capsules and oral suspension for $2mm.

Pernix Therapeutics Announces Sale of Non-Core Product

MORRISTOWN, N.J., Nov. 06, 2017 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) (“Pernix” or the “Company”), a specialty pharmaceutical company, today announced the sa...

Pernix Therapeutics Reports Third Quarter 2017 Financial Results

MORRISTOWN, N.J., Nov. 07, 2017 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) (“Pernix” or the “Company”), a specialty pharmaceutical company, announced today financ...

Pernix Therapeutics Announces Planned Departure of Chief Financial Officer

MORRISTOWN, N.J., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) (“Pernix” or the “Company”), a specialty pharmaceutical company, today announced that G...

Pernix Therapeutics' (PTX) CEO John Sedor on Q2 2017 Results - Earnings Call Transcript

Pernix Therapeutics Announces Election of Two Healthcare Industry Veterans to Board of Directors

MORRISTOWN, N.J., Nov. 16, 2017 (GLOBE NEWSWIRE) -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX) (“Pernix” or the “Company”), a specialty pharmaceutical company, today announced the el...

PubMed Articles [427 Associated PubMed Articles listed on BioPortfolio]

Unique architecture of thermophilic archaeal virus APBV1 and its genome packaging.

Archaeal viruses have evolved to infect hosts often thriving in extreme conditions such as high temperatures. However, there is a paucity of information on archaeal virion structures, genome packaging...

Pig movements in France: Designing network models fitting the transmission route of pathogens.

Pathogen spread between farms results from interaction between the epidemiological characteristics of infectious agents, such as transmission route, and the contact structure between holdings. The obj...

Response to Aslankurt et al. re: "Safety Profile of Stromal Hydration of Clear Corneal Incisions with Cefuroxime in the Mouse Model".

Is the Eye an Extension of the Brain in Central Nervous System Disease?

Modelling virus coinfection to inform management of maize lethal necrosis in Kenya.

Maize lethal necrosis (MLN) has emerged as a serious threat to food security in sub-Saharan Africa. MLN is caused by coinfection with two viruses, maize chlorotic mottle virus (MCMV) and a potyvirus, ...

Clinical Trials [122 Associated Clinical Trials listed on BioPortfolio]

Impact of Ibis on Patients With Advanced COPD

The purpose of this research is to determine if Ibis™, a digital therapeutics solution developed by Senscio Systems, reduces the emergency room visits and hospitalizations of patients wi...

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

Assess the effect on coronary atheroma of serial infusions of autologous selectively delipidated HDL/preβ enriched plasma following use of HDL Therapeutics PDS-2™ System

Ontogenesis of the P-Glycoprotein in Human Lymphocytes Influence of HIV and Antiretroviral Therapeutics

The P-glycoprotein (P-gp) is a membranous transporter that modulates the intracellular concentrations of many drugs and plays thus a major role in the efficacy of the therapeutics that act...

A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered i...

A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer

This is an open label, multi-center, Phase 1/2 study of BBI503 administered in combination with selected anti-cancer therapeutics in adult patients with advanced cancer. The goal of the st...

Companies [1574 Associated Companies listed on BioPortfolio]

Pernix Therapeutics Holdings, Inc.

Pernix Therapeutics Holdings, Inc. is a specialty pharmaceutical company primarily focused on serving the needs of the pediatric marketplace. Commercially-proven branded product f...

Auven Therapeutics

Auven Therapeutics is a private equity company focused on the healthcare industry. The Company’s strategy is to acquire controlling ownership in promising therapeutic products or platforms. ...

InVivo Therapeutics Holdings Corp.

InVivo Therapeutics Holdings Corp. is a Cambridge, MA medical device company focused on utilizing polymers as a platform technology to develop treatments to improve function in in...

FORMA Therapeutics Holdings, LLC

Lixte Biotechnology Holdings, Inc.

Lixte Biotechnology Holdings, Inc. is a cancer therapeutics and diagnostics company. Founded as a biomarker-diagnostics company in 2005, Lixte develops new chemotherapy drugs targeting molecular ...

More Information about "Pernix Therapeutics Holdings, Inc." on BioPortfolio

We have published hundreds of Pernix Therapeutics Holdings, Inc. news stories on BioPortfolio along with dozens of Pernix Therapeutics Holdings, Inc. Clinical Trials and PubMed Articles about Pernix Therapeutics Holdings, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Pernix Therapeutics Holdings, Inc. Companies in our database. You can also find out about relevant Pernix Therapeutics Holdings, Inc. Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topic

Pediatrics
Pediatrics is the general medicine of childhood. Because of the developmental processes (psychological and physical) of childhood, the involvement of parents, and the social management of conditions at home and at school, pediatrics is a specialty. With ...


Corporate Database Quicklinks



Searches Linking to this Company Record